Schering In Talks With Potential Partners For HDL Cholesterol Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering and Merck’s cholesterol franchise continues to gain growth in terms of market share, but sequential sales of the combination therapy Vytorin fall flat.